Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kelly Lyons is active.

Publication


Featured researches published by Kelly Lyons.


American Journal of Human Genetics | 2003

Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease

Joelle M. van der Walt; Eden R. Martin; William K. Scott; Martha Nance; Ray L. Watts; Jean Hubble; Jonathan L. Haines; William C. Koller; Kelly Lyons; Rajesh Pahwa; Matthew B. Stern; Amy Colcher; Bradley C. Hiner; Joseph Jankovic; William G. Ondo; Fred H. Allen; Christopher G. Goetz; Gary W. Small; F.L. Mastaglia; Jeffrey M. Stajich; Adam McLaurin; Lefkos T. Middleton; Burton L. Scott; Donald E. Schmechel; Margaret A. Pericak-Vance; Jeffery M. Vance

Mitochondrial (mt) impairment, particularly within complex I of the electron transport system, has been implicated in the pathogenesis of Parkinson disease (PD). More than half of mitochondrially encoded polypeptides form part of the reduced nicotinamide adenine dinucleotide dehydrogenase (NADH) complex I enzyme. To test the hypothesis that mtDNA variation contributes to PD expression, we genotyped 10 single-nucleotide polymorphisms (SNPs) that define the European mtDNA haplogroups in 609 white patients with PD and 340 unaffected white control subjects. Overall, individuals classified as haplogroup J (odds ratio [OR] 0.55; 95% confidence interval [CI] 0.34-0.91; P=.02) or K (OR 0.52; 95% CI 0.30-0.90; P=.02) demonstrated a significant decrease in risk of PD versus individuals carrying the most common haplogroup, H. Furthermore, a specific SNP that defines these two haplogroups, 10398G, is strongly associated with this protective effect (OR 0.53; 95% CI 0.39-0.73; P=.0001). SNP 10398G causes a nonconservative amino acid change from threonine to alanine within the NADH dehydrogenase 3 (ND3) of complex I. After stratification by sex, this decrease in risk appeared stronger in women than in men (OR 0.43; 95% CI 0.27-0.71; P=.0009). In addition, SNP 9055A of ATP6 demonstrated a protective effect for women (OR 0.45; 95% CI 0.22-0.93; P=.03). Our results suggest that ND3 is an important factor in PD susceptibility among white individuals and could help explain the role of complex I in PD expression.


Movement Disorders | 2001

Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor.

William C. Koller; Kelly Lyons; Steven B. Wilkinson; Alexander I. Tröster; Rajesh Pahwa

Our objective was to investigate the long‐term safety and efficacy of unilateral deep brain stimulation (DBS) of the VIM nucleus of the thalamus in essential tremor. Forty‐nine patients were evaluated for DBS between December 1993 and March 1998. Tremor was assessed by a clinical rating scale at 3 and 12 months and then yearly. Three patients were not implanted, seven were explanted prior to 24 months, 11 were lost to long‐term follow‐up, and three died from unrelated causes. Twenty‐five patients were evaluated with follow‐up greater than or equal to 2 years. The last postsurgical follow‐up occurred on average 40.2 ± 14.7 months after surgery. Tremor scores were significantly improved with stimulation on at the long‐term follow‐up as compared to baseline. There was no change in tremor scores from baseline to long‐term follow‐up with stimulation off. There was no significant change in any stimulus parameters from 3 months to the long‐term follow‐up. Three patients had asymptomatic intracerebral hemorrhages and one patient had postoperative seizures. Stimulus‐related adverse reactions were mild and easily controlled with changes in stimulus parameters. Device‐related complications were common and required repeated surgical procedures. Unilateral DBS of the thalamus has long‐term efficacy in some patients for treatment of essential tremor. However, this therapy is compromised by loss of efficacy in some patients and device complications which increase the risk of additional surgical procedures.


Neurology | 2003

Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease

Tatiana Foroud; Sean K. Uniacke; L. Liu; Nathan Pankratz; Alice Rudolph; Cheryl Halter; Clifford W. Shults; Karen Marder; P.M. Conneally; William C. Nichols; Lawrence I. Golbe; William C. Koller; Kelly Lyons; Frederick Marshall; David Oakes; Aileen Shinaman; Eric Siemers; Joanne Wojcieszek; Joann Belden; Julie H. Carter; Richard Camicioli; Pamela Andrews; Magali Fernandez; Jean Hubble; Carson Reider; Ali H. Rajput; Alex Rajput; Theresa Shirley; Michael Panisset; Jean Hall

Background: The vast majority of the parkin mutations previously identified have been found in individuals with juvenile or early onset PD. Previous screening of later onset PD cohorts has not identified substantial numbers of parkin mutations. Methods: Families with at least two siblings with PD were ascertained to identify genes contributing to PD susceptibility. Screening of the parkin gene, by both quantitative PCR and exon sequencing, was performed in those families with either early onset PD (age onset ≤50 years) or positive lod score with a marker in intron 7 of the parkin gene. Results: A total of 25 different mutations in the parkin gene were identified in 103 individuals from 47 families. Mutations were found in both parkin alleles in 41 of the individuals, whereas a single mutation in only one of the two parkin alleles was observed in 62 individuals. Thirty-five of the subjects (34%) with a parkin mutation had an age at onset of 60 years or above with 30 of these 35 (86%) having a detectable mutation on only one parkin allele. Few significant clinical differences were observed among the individuals with two, one, or no mutated copies of the parkin gene. Conclusion: Mutations in the parkin gene occur among individuals with PD with an older age at onset (≥60 years) who have a positive family history of the disease. In addition, the clinical findings of parkin-positive individuals are remarkably similar to those without mutations.


American Journal of Human Genetics | 2003

Significant Linkage of Parkinson Disease to Chromosome 2q36-37

Nathan Pankratz; William C. Nichols; Sean K. Uniacke; Cheryl Halter; Alice Rudolph; Cliff Shults; P. Michael Conneally; Tatiana Foroud; Lawrence I. Golbe; William C. Koller; Kelly Lyons; Karen Marder; Frederick Marshall; David Oakes; Aileen Shinaman; Eric Siemers; Joanne Wojcieszek; Joann Belden; Julie H. Carter; Richard Camicioli; Pamela Andrews; Magali Fernandez; Jean Hubble; Carson Reider; Ali H. Rajput; Alex Rajput; Theresa Shirley; Michel Panisset; Jean Hall; Tilak Mendis

Parkinson disease (PD) is the second most common neurodegenerative disorder, surpassed in frequency only by Alzheimer disease. Elsewhere we have reported linkage to chromosome 2q in a sample of sibling pairs with PD. We have now expanded our sample to include 150 families meeting our strictest diagnostic definition of verified PD. To further delineate the chromosome 2q linkage, we have performed analyses using only those pedigrees with the strongest family history of PD. Linkage analyses in this subset of 65 pedigrees generated a LOD score of 5.1, which was obtained using an autosomal dominant model of disease transmission. This result strongly suggests that variation in a gene on chromosome 2q36-37 contributes to PD susceptibility.


Neurology | 2001

A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor

Mitchell F. Brin; Kelly Lyons; J. Doucette; Charles H. Adler; John N. Caviness; Cynthia L. Comella; Richard Dubinsky; Joseph H. Friedman; B. V. Manyam; Joseph Y. Matsumoto; Seth L. Pullman; Ali H. Rajput; Kapil D. Sethi; Tanner Cm; William C. Koller

Objective: To evaluate the safety and efficacy of botulinum toxin type A injection in essential tremor of the hand. Background: Botulinum toxin type A is an effective treatment for dystonia, spasticity, and other movement disorders and has been found to be useful in open-label studies and one double-masked study of essential hand tremor. Methods: One hundred thirty-three patients with essential tremor were randomized to low-dose (50 U) or high-dose (100 U) botulinum toxin type A (Botox) or vehicle placebo treatment. Injections were made into the wrist flexors and extensors. Patients were followed for 16 weeks. The effect of treatment was assessed by clinical rating scales, measures of motor tasks and functional disability, and global assessment of treatment. Hand strength was evaluated by clinical rating and by a dynamometer. Results: Both doses of botulinum toxin type A significantly reduced postural tremor on the clinical rating scales after 4 to 16 weeks. However, kinetic tremor was significantly reduced only at the 6-week examination. Measures of motor tasks and functional disability were not consistently improved with botulinum toxin type A treatment. Grip strength was reduced for the low- and high-dose botulinum toxin type A groups as compared with the placebo group. Adverse reactions consisted mainly of dose-dependent hand weakness. Conclusion: Botulinum toxin type A injections for essential tremor of the hands resulted in significant improvement of postural, but not kinetic, hand tremors and resulted in limited functional efficacy. Hand weakness is a dose-dependent significant side effect of treatment at the doses used in this study.


European Journal of Neurology | 2002

Neuropsychological deficits in essential tremor: an expression of cerebello‐thalamo‐cortical pathophysiology?

Alexander I. Tröster; Steven Paul Woods; Julie A. Fields; Kelly Lyons; Rajesh Pahwa; C. I. Higginson; William C. Koller

Few studies have been published regarding the neuropsychological characteristics of patients with essential tremor (ET), but preliminary findings suggest that mild attentional and executive dysfunction accompany the disorder. A consecutive series of 101 patients with ET referred for thalamotomy and/or thalamic deep brain stimulation candidacy work‐up also underwent neuropsychological evaluation. Average neuropsychological test scores were calculated, along with the proportions of subjects whose scores fell within or more than one SD above or below the mean (using demographically corrected normative data). Significantly lower than average (T‐score of 50) scores were evident on measures of complex auditory attention, visual attention and response inhibition, recall of a word list, verbal fluency, and visual confrontation naming. A significantly greater proportion of patients (ranging from about 34 to 60%) than might be expected on the basis of a normal distribution obtained scores more than one SD below the normative mean on select measures of attention, verbal fluency, immediate word list recall, semantic encoding, and facial matching. Consistent with prior research, notable, albeit clinically subtle, deficits in attention and select executive functions are evident in patients with ET. Although not specific to ET or cerebellar dysfunction, the observed pattern of cognitive deficits is consistent with cerebello‐thalamo‐cortical circuit dysfunction.


Movement Disorders | 2001

Comparison of thalamotomy to deep brain stimulation of the thalamus in essential tremor

Rajesh Pahwa; Kelly Lyons; Steven B. Wilkinson; Alexander I. Tröster; John Overman; Jennifer Kieltyka; William C. Koller

To compare outcome in Essential Tremor (ET) patients who have undergone either thalamotomy or Deep Brain Stimulation (DBS) of the thalamus.


Annals of Neurology | 2001

Functional correlates of pallidal stimulation for Parkinson's disease

Masafumi Fukuda; Marc J. Mentis; Maria Felice Ghilardi; Vijay Dhawan; Angelo Antonini; John P. Hammerstad; Andres M. Lozano; Anthony E. Lang; Kelly Lyons; William C. Koller; Claude Ghez; David Eidelberg

We measured regional cerebral blood flow with H215O and positron emission tomography (PET) scanning at rest and during a motor task to study the mechanism of motor improvement induced by deep brain stimulation of the internal globus pallidus in Parkinsons disease. Six right‐handed patients with Parkinsons disease were scanned while performing a predictable paced sequence of reaching movements and while observing the same screen displays and tones. PET studies were performed ON and OFF stimulation in a medication‐free state. Internal globus pallidus deep brain stimulation improved off‐state United Parkinsons Disease Rating Scale motor ratings (37%, p < 0.002) and reduced timing errors (movement onset time, 55%, p < 0.01) as well as spatial errors (10%, p < 0.02). Concurrent regional cerebral blood flow recordings revealed a significant enhancement of motor activation responses in the left sensorimotor cortex (Brodmann area [BA] 4), bilaterally in the supplementary motor area (BA 6), and in the right anterior cingulate cortex (BA 24/32). Significant correlations were evident between the improvement in motor performance and the regional cerebral blood flow changes mediated by stimulation. With internal globus pallidus deep brain stimulation, improved movement initiation correlated with regional cerebral blood flow increases in the left sensorimotor cortex and ventrolateral thalamus and in the contralateral cerebellum. By contrast, improved spatial accuracy correlated with regional cerebral blood flow increases in both cerebellar hemispheres and in the left sensorimotor cortex. These results suggest that internal globus pallidus deep brain stimulation may selectively improve different aspects of motor performance. Multiple, overlapping neural pathways may be modulated by this intervention. Ann Neurol 2001:49:155–164


Journal of Neurology, Neurosurgery, and Psychiatry | 2003

Neuropsychological and quality of life outcomes 12 months after unilateral thalamic stimulation for essential tremor

Julie A. Fields; Alexander I. Tröster; Steven Paul Woods; C. I. Higginson; Steve Wilkinson; Kelly Lyons; William C. Koller; Rajesh Pahwa

Objectives: To evaluate the one year cognitive, mood state, and quality of life (QoL) outcomes of unilateral thalamic deep brain stimulation (DBS) for essential tremor (ET). Methods: 40 patients diagnosed with ET completed comprehensive neuropsychological assessments about one month before and three and 12 months after DBS electrode implantation. Data were subjected to multivariate analyses, and significant results were further analysed using univariate techniques. Results: Analyses revealed statistically significant improvements on a cognitive screening measure and in aspects of fine visuomotor and visuoperceptual functions, verbal memory, mood state, and QoL. No group-wise declines in cognition were observed, but more patients showed declines than improvements on language and visual memory tests. Semantic verbal fluency declined significantly in four (10%) of the patients. In these four patients, diminished lexical verbal fluency was present at baseline. Conclusion: Cognitive, mood, and QoL outcomes after one year of DBS for ET are favourable; there were no overall deleterious effects on cognition, and DBS was accompanied by a significant reduction in anxiety and improvements in quality of life. However, preoperative verbal fluency diminution may predispose to further fluency declines after DBS.


Journal of Neurology, Neurosurgery, and Psychiatry | 2001

Long term safety and efficacy of unilateral deep brain stimulation of the thalamus for parkinsonian tremor

Kelly Lyons; William C. Koller; Steve Wilkinson; Rajesh Pahwa

The objective was to investigate the long term safety and efficacy of unilateral deep brain stimulation (DBS) of the VIM nucleus of the thalamus in Parkinsons disease. Twelve patients with Parkinsons disease underwent unilateral DBS of the thalamus for medication resistant tremor between 1994 and 1997. Patients were evaluated with the motor section of the unified Parkinsons disease rating scale (UPDRS) in the medication on state at baseline, 3 months, 12 months, and yearly thereafter. Three patients were lost to follow up. Nine patients had follow up evaluations greater than 24 months and were included in the analyses. The last postsurgical follow up occurred on average 40.0 (SD 17.2) months after surgery. Tremor scores were significantly improved with stimulation on at the long term follow up compared with baseline. There was no significant change in UPDRS motor scores at long term follow up compared with baseline. There was no significant change in any stimulus parameters from 3 months to the long term follow up. Two patients had asymptomatic intracerebral haemorrhages and one patient had a subcutaneous haematoma over the implantable pulse generator site. Stimulus related adverse reactions were mild and easily controlled with changes in stimulus parameters. Two patients had replacement of the implantable pulse generator due to normal battery depletion, one patient had lead repositioning due to migration, and one patient had the lead extension wire replaced due to erosion. In conclusion,unilateral DBS of the thalamus has long term efficacy for treatment of tremor due to Parkinsons disease.

Collaboration


Dive into the Kelly Lyons's collaboration.

Top Co-Authors

Avatar

Rajesh Pahwa

University of Hawaii at Manoa

View shared research outputs
Top Co-Authors

Avatar

William C. Koller

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joseph Jankovic

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christopher G. Goetz

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martha Nance

Hennepin County Medical Center

View shared research outputs
Top Co-Authors

Avatar

Matthew B. Stern

University of Pennsylvania

View shared research outputs
Researchain Logo
Decentralizing Knowledge